Understand · Treat · Recover

Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma includes many diseases. This chapter introduces the major patterns without treating them as one illness.

For patients and families. This education does not replace an individual treatment plan. Do not start, stop or change medicines without the treating team.

Chapter 10 of 20 · C · Lymphoma

DLBCL: a fast-growing, potentially curable lymphoma

Diffuse large B-cell lymphoma (DLBCL) usually needs prompt treatment. R-CHOP is a widely used antibody–chemotherapy combination; polatuzumab-containing R-CHP is an option for selected patients. Pathology, disease risk, heart health and access help determine the regimen. Certain MYC and BCL2 rearrangements can identify high-risk biology and affect planning; protein expression by IHC is not the same as a gene rearrangement by FISH. Radiotherapy is useful in selected situations.

Follicular lymphoma: different goals at different stages

Some localized follicular lymphomas can be treated with radiotherapy with curative intent. Advanced indolent disease is commonly managed for prolonged control. Observation may be appropriate when disease is asymptomatic and low burden. Treatment can include anti-CD20 antibodies, combinations with chemotherapy or other medicines. A new rapidly growing node or new systemic symptoms may suggest transformation and prompt repeat biopsy. Higher-grade entities may need an aggressive-lymphoma approach.

Mantle cell lymphoma

Mantle cell lymphoma has variable behavior; some selected indolent presentations can be observed, but many need treatment. Approaches may combine antibodies, chemotherapy and BTK inhibitors, with maintenance or autologous transplantation in selected settings. Cellular therapy and newer targeted options can be relevant after relapse. TP53 abnormalities, fitness and previous treatment influence decisions. It is usually approached as a disease needing long-term management rather than a guaranteed cure.

Burkitt lymphoma

Burkitt lymphoma can grow extremely quickly and needs urgent specialist treatment. Intensive, disease-specific regimens include CNS-directed care. Tumor lysis syndrome can occur even before treatment, making hospital monitoring and prevention vital. Despite its speed, it can be curable. It should not be managed with a generic slow-lymphoma plan.

Peripheral T-cell and other lymphomas

Peripheral T-cell lymphomas are a diverse group and generally require expert classification. Some CD30-positive diseases use brentuximab-containing therapy; other subtypes require different regimens. Transplant may be considered for selected patients. NK/T-cell lymphoma and primary CNS lymphoma need particularly distinct approaches. A B-cell drug such as rituximab is not automatically useful for a T-cell lymphoma.

Relapsed or refractory disease

Refractory means resistant to treatment; relapsed means disease has returned after a response. Repeat tissue sampling can confirm the diagnosis or transformation. Depending on subtype and timing, options include salvage chemotherapy, autologous transplantation, CAR-T cells, bispecific antibodies, antibody-drug conjugates, targeted drugs or a trial. CAR-T is established in selected B-cell lymphoma settings, including some early relapses; it is not suitable or available for every lymphoma. Bispecific treatment has its own infection, cytokine-release and neurological risks.

Questions that make the plan clearer

  • What is the complete subtype, and is the goal cure or control?
  • Do any pending FISH or molecular results change the regimen?
  • What emergency access and infection prevention are needed?
  • If the first treatment fails, which realistic options exist locally or by referral?

Take-home message

The subtype and relapse timing guide treatment; “non-Hodgkin lymphoma” is only the starting label.

Common questions

Is an aggressive lymphoma worse than every slow lymphoma?

Not necessarily. Some fast-growing lymphomas respond very well and can be cured. Biology and response matter more than the adjective alone.

Can the same treatment be reused after relapse?

Sometimes, but not automatically. The subtype, time since treatment and prior resistance or toxicity guide the next choice.

Sources and further reading

Cancer Aware supports patients and families worldwide. Treatment availability, approvals and care pathways vary by country; discuss local options with your healthcare team.